Introduction {#sec1}
============

Well-documented disparities exist in prostate cancer incidence, morbidity, and mortality in black versus white males in the United States.[@bib1], [@bib2] Identifying appropriate candidates for active surveillance using only traditional risk stratification parameters (prostate specific antigen \[PSA\], Gleason score, and tumor stage) remains challenging particularly when considering black race. Recent analyses from Johns Hopkins found that black men classified as having very low-risk prostate cancer, technically eligible for active surveillance, were more likely to have adverse pathologic features at the time of radical prostatectomy,[@bib3] as well as larger dominant intraprostatic lesions (IPLs) with high prevalence of anterior foci.[@bib4] A higher risk of disease progression in black men after enrollment on active surveillance trials has similarly been confirmed in other cohorts with larger numbers of black men.[@bib5] There is increased interest in incorporating additional tools, such as multiparametric magnetic resonance imaging (mpMRI), into risk stratification paradigms given its ability to detect otherwise occult high-risk features.

Multiparametric MRI with diffusion-weighted imaging and dynamic contrast enhancement sequences allow for the identification of dominant IPLs.[@bib6] Prior diagnostic literature has demonstrated that IPL characteristics, such as their apparent diffusion coefficient,[@bib7] contrast agent transfer rate between blood and tissue,[@bib8] extracapsular extension,[@bib9] and seminal vesicle invasion,[@bib10] are associated with other known prognostic indicators such as the PSA, Gleason score, and risk group.[@bib9] Pathologic correlation with prostatectomy specimens has demonstrated the accuracy of these findings.[@bib11] Increasingly, a relationship between pre-radiation therapy MRI findings, such as IPL size, extracapsular extension, and seminal vesicle invasion, and long-term outcomes, such as biochemical relapse and metastases, has been demonstrated[@bib12], [@bib13], [@bib14], [@bib15]; however, existing nomograms used in predicting prostate cancer biochemical relapse after external-beam radiation therapy, such as the Kattan nomogram[@bib16] generally do not currently include these imaging parameters.

The increasing body of evidence that supports the use of mpMRI underscores the importance of performing research to quantify its dissemination. Although prostate mpMRI may have the potential to reduce prostate cancer disparities by improving risk stratification, it is unclear how often this technology is used across different clinical risk and demographic groups. Known cancer health disparities exist in imaging in other malignancies, such as breast,[@bib17] colon,[@bib18] and lung[@bib19] cancer, but have not been well explored or documented in prostate cancer, and health care resource utilization may additionally serve as a measure of access to care.[@bib20] Thus, the aim of our study was to determine whether disparities exist in mpMRI utilization across risk groups in men with prostate cancer undergoing definitive radiation therapy.

Methods and materials {#sec2}
=====================

We conducted an institutional review board--approved retrospective analysis of prostate cancer patients treated with definitive external beam radiation therapy with curative intent at a single academic institution between November 2005 and December 2013. Existing medical databases and electronic medical records were used to identify all patients (N = 705) treated with histologically confirmed, nonmetastatic adenocarcinoma of the prostate. We collected pretreatment demographic characteristics, including age, race, socioeconomic status (SES), distance in miles from home address to the radiation facility, and primary insurance, primary treating radiation oncologist, and treatment year. Racial groups included white, black, Asian, other, and unknown; Asian and unknown were combined with other for this analysis given their small numbers in the cohort. As a surrogate for SES, we used the federal definition of residing in poverty based on geocoded census tract.[@bib21] Distance was classified as \<45 miles or ≥45 miles from the radiation treatment facility as a surrogate for patients residing locally or regionally versus those traveling more distantly. A total of 95% of patients received staging MRI at the same facility. Primary insurance type was classified as either private or nonprivate, which included Medicare and Medicaid. Pretreatment PSA, treatment-recorded clinical tumor stage (as assessed by digital rectal exam or imaging), Gleason score, D\'Amico risk stratification group,[@bib22] percentage of positive biopsy cores, International Prostate Symptom Score (IPSS), date of prostate cancer diagnosis, treatment dates, and pretreatment usage of diagnostic prostate and/or pelvic mpMRI (including T2-weighted, diffusion-weighted, and/or dynamic contrast-enhanced sequences, 91% with endorectal coil), were retrospectively recorded through chart review. Patients were divided into comparison groups based on whether they did or did not undergo pretreatment diagnostic prostate mpMRI. Six patients with explicitly recorded contraindications to mpMRI were excluded from the analysis, leaving 609 patients assessed. During the treatment time frame, our institution-wide standard practice guideline encouraged a diagnostic MRI in all-risk prostate cancer patients without contraindications.

Statistical considerations {#sec2.1}
--------------------------

The primary objective was to compare demographic and clinical characteristics of prostate cancer patients who either did or did not undergo pretreatment diagnostic mpMRI at our institution. Descriptive statistics were computed for the overall cohort and then MRI versus non-MRI utilization groups were compared using the χ^2^ test for categorical variables and the Student *t* test for continuous variables. Age, PSA, distance, percentage of positive biopsy cores, and IPSS were analyzed as continuous variables, and the remainder as categorical. All *P* values were 2-sided. Univariable logistic regression was used to evaluate the relationship of clinical and demographic characteristics with MRI utilization as the outcome variable. Multivariable logistic regression models were constructed using variables significant in the univariable analysis. Multivariable analysis was stratified by risk group to best approximate clinical practice and decision making at the common point of MRI utilization. Odds ratios (OR) were reported with associated 95% confidence intervals (CI). A *P* value \<.05 was considered statistically significant. Analyses were conducted using either STATA/MP 13 (College Station, TX) or SAS, version 9.4 (Cary, NC).

Results {#sec3}
=======

[Table 1](#tbl1){ref-type="table"} shows the overall cohort and comparison of characteristics for those who underwent MRI compared with those who did not. Demographically, patients who did not undergo MRI were significantly older (mean age 67 vs 71), and more likely to reside in poverty (36% vs 23%), live closer to the facility (\<45 miles), have nonprivate primary insurance, and be of black race (all *P* values \< .05). The percentages of whites, blacks, and the other race group undergoing MRI were 80% (343/427), 68% (156/231), and 85% (40/47), respectively. There was also increasing MRI utilization over time. Regarding clinical characteristics, patients undergoing MRI were more likely to have clinical stage T3 disease (11.7% vs 3.6%); the cohorts did not differ by PSA (mean 10.5 vs 9.3), Gleason score, risk group, percentage positive biopsy cores, or IPSS, respectively, for the cohort that had an MRI versus the cohort that did not.Table 1Overall cohort characteristics and comparison of prostate multiparametric MRI vs non-MRI cohortVariableCharacteristicOverallNo staging MRIStaging MRI*P* valueN (%)705166539Age (y)Mean ± SD67.1 ± 7.970.7 ± 7.865.9 ± 7.6\<.001RaceWhite427 (60.6)84 (50.6)343 (63.6)\<.001Black231 (32.8)75 (45.2)156 (28.9)Other47 (6.7)7 (4.2)40 (7.4)PovertyNo521 (73.9)106 (63.9)415 (77.0)\<.001Yes184 (26.1)60 (36.1)124 (23.0)Distance (miles)\<45556 (78.9)142 (85.5)414 (76.8).016≥45149 (21.1)24 (14.5)125 (23.2)Primary insurancePrivate243 (34.5)42 (25.3)201 (37.3).005Nonprivate462 (65.5)124 (74.7)338 (62.7)Treatment year2005-2007159 (22.6)77 (48.4)82 (51.6)\<.0012008-2009129 (18.3)49 (38.0)80 (62.0)2010-2013417 (59.1)40 (9.6)377 (90.4)PSA (ng/mL)Mean ± SD9.6 ± 14.210.5 ± 15.39.3 ± 13.8.351Gleason score6290 (41.1)65 (39.2)225 (41.7).4397325 (46.1)75 (45.2)250 (46.4)852 (7.4)13 (7.8)39 (7.2)938 (5.4)13 (7.8)25 (4.6)Clinical T stageT1502 (71.2)122 (73.5)380 (70.5).006T2134 (19.0)38 (22.9)96 (17.8)T369 (9.8)6 (3.6)63 (11.7)Risk groupHigh151 (21.4)40 (24.1)111 (20.6).578Intermediate308 (43.7)68 (41.0)240 (44.5)Low246 (34.9)58 (34.9)188 (34.9)Percent positive biopsy coresMean ± SD0.4 ± 0.30.4 ± 0.30.4 ± 0.3.348IPSSMean ± SD7.9 ± 6.58.2 ± 6.17.8 ± 6.6.590[^1]

On univariable logistic regression ([Table 2](#tbl2){ref-type="table"}), all demographic variables assessed, except for the other race category, were associated with MRI utilization, including age (OR, 0.92; 95% CI, 0.89-0.94; *P* \< .05), black race (OR, 0.51, 0.35, 0.73; *P* \< .05), poverty (OR, 0.53, 0.36, 0.77; *P* \< .05), distance (OR, 1.79; 1.11, 2.88; *P* \< .05), and primary insurance type (OR, 0.57, 0.39, 0.84; *P* \< .05). Only clinical stage T3 (OR, 3.37, 1.42, 7.97; *P* \< .05) was associated with MRI utilization, whereas treatment year and the other clinical characteristics assessed---PSA, Gleason score, clinical stage, risk group, percent positive cores, and IPSS---were not.Table 2Univariable association of demographic and clinical characteristics with staging MRIIndependent variableCharacteristicOR (95% CI)*P* valueAge (y)0.92 (0.89-0.94)\<.001RaceBlack vs white0.51 (0.35-0.73)\<.001Other vs white1.40 (0.61-3.23).432PovertyYes vs no0.53 (0.36-0.77)\<.001Distance (miles)≥45 vs \<451.79 (1.11- 2.88).017Primary insuranceNonprivate vs private0.57 (0.39-0.84).005Treatment Year2008-2009 vs 2005-20070.43 (−0.05 to 2.63).0762010-2013 vs 2005-20071.40 (0.61-3.23).432PSA (ng/mL)0.99 (0.98-1.01).354Gleason score7 vs 60.96 (0.66-1.41).8458 vs 60.87 (0.44-1.72).6839 vs 60.56 (0.27-1.15).112Clinical T stageT2 vs T10.81 (0.53-1.24).337T3 vs T13.37 (1.42-7.97).006Risk groupIntermediate vs high1.27 (0.81-2.00).296Low vs high1.17 (0.73-1.86).514Percent positive biopsy cores0.64 (0.25-1.63).348IPSS0.99 (0.95-1.03).589[^2]

The results of the multivariable logistic regression stratified by risk group are shown in [Table 3](#tbl3){ref-type="table"}. Age was associated with MRI utilization in all risk groups. Black versus white race (OR, 0.21, 0.08, 0.55; *P* \< .05) and nonprivate versus private insurance (OR, 0.37, 0.16, 0.86; *P* \< .05) were associated with MRI utilization in the low-risk group ([Fig 2](#fig2){ref-type="fig"}). Clinical stage T3 remained associated with MRI utilization in the high-risk group.Figure 1Percentage prostate MRI utilization by (A) age, (B) race, and (C) insurance type and prostate cancer risk groups. \*Represents significant difference; error bars represent the 95% confidence interval. Int, intermediate.Figure 2Plot of adjusted\* (dashed line) and unadjusted (solid line) odds ratios of prostate magnetic resonance imaging utilization for black vs white men from the multivariable analysis stratified by risk-group. \*Adjusted for age, poverty, primary insurance type, distance, and clinical stage.Table 3Risk group stratified multivariable association of demographic and clinical characteristics with staging MRIRisk groupVariableCharacteristicOR (95% CI)*P* valueLowAge0.89 (0.84-0.94)\<.001RaceBlack vs white0.21 (0.08-0.55).001Other vs white0.22 (0.06-0.77).018PovertyYes vs no0.64 (0.25-1.64).353Primary insuranceNonprivate vs private0.37 (0.16-0.86).020Distance (miles)≥45 vs \<451.28 (0.48-3.44).623Clinical T stageT2 vs T10.51 (0.19-1.40).193IntermediateAge0.94 (0.90-0.97)\<.001RaceBlack vs white0.71 (0.29-1.73).454Other vs white5.57 (0.71-43.8).103PovertyYes vs no0.98 (0.39-2.47).973Primary insuranceNonprivate vs private1.03 (0.55-1.93).930Distance (miles)≥45 vs \<451.26 (0.59, 2.71).551Clinical T stageT2 vs T11.38 (0.66-2.85).390HighAge0.93 (0.88-0.98).013RaceBlack vs white0.99 (0.34-2.87).989Other vs whiteNENEPovertyYes vs no0.92 (0.30-2.79).879Primary insuranceNonprivate vs private0.79 (0.31-2.01).623Distance (miles)≥45 vs \<451.03 (0.31-3.42).967Clinical T stageT2 vs T10.52 (0.20-1.34).176T3 vs T13.75 (1.25-11.3).019[^3]

[Figure 1](#fig1){ref-type="fig"} shows MRI utilization by risk group and the variables significant on multivariable analysis---age, race, and insurance type. For age ([Fig 1](#fig1){ref-type="fig"}A), the percentages of men younger than age 65 compared with ≥65 undergoing MRI in the low-, intermediate-, and high-risk groups were, respectively, 91% versus 67%, 86% versus 73%, and 86% versus 68% (all *P* \< .05). For race ([Fig 1](#fig1){ref-type="fig"}B), the percentages of whites and blacks undergoing MRI were 86% and 56%, in the low-risk group, 79% and72% in the intermediate-risk group, and 72% and 72% in the high-risk group, respectively. The percentages of patients with private insurance compared to nonprivate ([Fig 1](#fig1){ref-type="fig"}C) undergoing MRI in the low-, intermediate-, and high-risk groups were, respectively, 87% versus 71% (*P* \< .05), 80% versus 76%, and 80% versus 70%.

Discussion {#sec4}
==========

In this urban, academic center cohort of nonmetastatic prostate cancer patients undergoing definitive radiation therapy, we explored whether clinical and demographic disparities exist in mpMRI utilization. We found that demographic characteristics, including age, race, poverty, and insurance type were associated with mpMRI utilization, whereas most clinical parameters, including PSA, Gleason score, and IPSS, were not. Patients not undergoing mpMRI were older and more likely to reside in poverty, live closer to the facility, have nonprivate primary insurance, and be of black race, indicating that demographic and not clinical characteristics most influenced mpMRI utilization. On multivariable analysis, age remained significant across all risk groups, and race and insurance type persisted only in the low-risk group.

Current National Cancer Comprehensive Network (NCCN) guidelines recommend cross-sectional imaging for all high-risk patients and also indicate that mpMRI may be used to risk-stratify patients who are considering active surveillance.[@bib23] American College of Radiology guidelines similarly recommend mpMRI in intermediate- and high-risk patients and indicate that MRI scans may be appropriate in low-risk patients considering active surveillance.[@bib24] Despite these staging guidelines and MRI\'s increasing role in aiding treatment selection and surgical and radiation planning,[@bib25] several studies have reported MRI use that is discordant with historical and present guidelines, including overutilization among low-risk patients and underutilization among high-risk patients.[@bib26], [@bib27] Although we do not postulate a "correct" utilization rate, in our study we did interestingly find disparate utilization trends by age, insurance type, and race. For race specifically, blacks ([Fig 1](#fig1){ref-type="fig"}) and the other category---patients that were neither white nor black---were significantly less likely to undergo mpMRI than whites in the low-risk group, but there were no significant differences in the intermediate- and high-risk groups, reassuringly suggesting equitable utilization by race in these more advanced risk groups. However, considering the emerging evidence for mpMRI in active surveillance[@bib28] in the context of racial disparities in prostate cancer, a plausible opportunity emerges to use this technology to improve staging in black men and positively affect management decisions. The racial disparity observed in our study is therefore very concerning, given that black men in the low-risk group who have been found to have high rates of disease progression,[@bib5] might arguably benefit most from the additional information offered by the mpMRI. As this was ultimately a treatment cohort, it would be important to verify the analysis in an active surveillance cohort to determine whether the utilization disparities pervade.

Racial disparities in imaging utilization have been well-described in other malignancies,[@bib17], [@bib18], [@bib19] but only to a limited extent in prostate cancer. An analysis from the Surveillance, Epidemiology and End Results-Medicare linked database evaluating staging workup before and after implementation of NCCN, American Urological Association, and American College of Radiology guidelines in 96,986 men with incident prostate cancer from 1991 to 1994 compared with 1995 to 1999 found that, of men who met guideline criteria for staging, black men were less likely to undergo bone scan and pelvic imaging than white men diagnosed from 1991 to 1994, but this racial difference was not seen from 1995 to 1999, suggesting historical improvements in disparate imaging trends. This parity was not noted in our study for patients in the low-risk group. In contrast, a more recent Surveillance, Epidemiology and End Results-Medicare analysis of prostate cancer patients diagnosed between 2004 and 2007 found that race was significantly associated with nonadherence to imaging guidelines on multivariable models, with bone scan and pelvic computed tomography (CT)/MRI overuse associated with non-white race (reference, white race).[@bib29] This same study did, however, find underuse of bone scan and pelvic CT/MRI associated with patient age \>79 years (reference age, 66-69), consistent with the age disparity found in our study. The age disparity seen in this previous report as well as our own study across risk groups was expectedly consistent with numerous studies in other malignancies demonstrating that older patients tend to have less rigorous staging workup than younger patients.[@bib30]

The reason behind these age and racial disparities is likely multifactorial, including SES, insurance status, provider biases, and access to care. However, in a single academic institution experience with standard therapeutic regimens, one might expect the impact of these demographic factors to be lessened or eliminated, as has been shown in a secondary analysis of black men enrolled on prostate radiation therapy cooperative group trials.[@bib31] This was not the case in our study. Finally, we did also find that private insurance type was associated with mpMRI utilization in the low-risk group. Being uninsured or having nonprivate insurance, such as Medicaid, has been consistently associated with poor health outcomes.[@bib32], [@bib33] Furthermore, patient insurance status has been shown to affect clinical decisions, both directly (ie, if the patient cannot afford the service) and indirectly by contributing to provider biases and preconceived notions that affect decision-making.[@bib32], [@bib34], [@bib35]

A limitation of our study is that it represents a radiation therapy cohort and whether such disparities in mpMRI utilization exist in other prostate cancer management cohorts (eg, active surveillance, surgical, metastatic) remains to be explored. Additionally, we did not record whether patients not obtaining mpMRI had alternative cross-sectional imaging, such as CT, given that mpMRI is superior to CT in identifying intraprostatic lesions and adverse tumor characteristics. Indeed, the association of clinical T3 stage on multivariable analysis and MRI utilization in our study potentially speaks to the superior local staging and anticipated tumor upstaging by mpMRI. We also intentionally excluded provider-level characteristics because we were retrospectively unable to capture the "true" ordering physician and it is unclear (however unlikely) that disparate patterns of mpMRI utilization may have systematically reflected different referral origins (ie, radiation oncology vs urology vs medical oncology vs primary care), despite institution wide preference for MRI as baseline staging. Similarly, it is unknown whether providers may have ordered the MRI scans, but they were not obtained by the patient due to financial, psychosocial, logistical, and other barriers. We did not exclude patients with explicit contraindication to MRI (3 of 166 not undergoing MRI) given the potential likelihood that other patients had absolute and relative contraindications that were not documented in the available records over the study period; it is uncertain how this may differ by demographics or risk group in this prostate cancer radiation therapy cohort. Regarding insurance status, because primary insurance type was recorded at the time of treatment, at which time all patients would have acquired insurance, insurance status at time of diagnosis was unknown, which may or may not have influenced mpMRI utilization. However, there is evidence that patients with either Medicaid or who are uninsured have similarly poorer cancer outcomes.[@bib36], [@bib37] Lastly, as a surrogate for SES, we used the federal definition of residing in poverty (\>20%) based on geocoded census tract coded as a binary outcome, which differed significantly at baseline, but not in multivariable analysis. Similar results were seen with the percent residing in poverty analyzed as a continuous variable (results not shown). Nonetheless, other SES surrogates such as median income or education level might have yielded an association with SES and helped to parse the complex association between race and SES.

Conclusions {#sec5}
===========

In this urban, academic center cohort, prostate cancer patients that were older, regardless of risk group, and that were black or with nonprivate insurance in the low-risk group, were less likely to undergo staging MRI. Collectively, these data raise areas for further practice review, analysis, and improvement, and should be undertaken on a wider scale as we embrace active surveillance, given the dearth of data on the safety and applicability of this strategy to black and older men. Given the known disproportionate burden of prostate cancer morbidity and mortality, further research should investigate whether MRI can help reduce prostate cancer disparities and is equitably used across all demographic groups.
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[^1]: IPSS, International Prostate Symptom Score; MRI, magnetic resonance imaging; PSA, prostate-specific antigen; SD, standard deviation.

[^2]: CI, confidence interval; IPSS, International Prostate Symptom Score; MRI, magnetic resonance imaging; OR, odds ratio; PSA, prostate-specific antigen.

[^3]: CI, confidence interval; MRI, magnetic resonance imaging; NE, not estimable due to small number of patients; OR, odds ratio.
